Title of article
Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?
Author/Authors
Cetinkalp, Sevki Ege University - Medical School - Department of Endocrinology and Metabolism, Turkey , Simsir, Ilgın Yildirim Ege University - Medical Faculty - Department of Endocrinology and Metabolism, Turkey , Sahin, Fahri Ege University Hospital - Departments of Hematology, Turkey , Saydam, Guray Ege University - Medical Faculty - Department of Hematology, Turkey , Ural, Ali Ugur Gülhane Military Medical Academy - School of Medicine - Department of Hematology, TURKEY , Yilmaz, Candeger Ege University - Medical School - Department of Endocrinology and Metabolism, Turkey
From page
14
To page
21
Abstract
PPARs are ligand-regulated transcription factors and regulate expression of several gene products. Therefore, PPARs are being studied for their possible contribution to the treatment of cancer, atherosclerosis, inflammation, infertility and demyelinating diseases. Primary AML patients were observed to have significantly elevated PPARɣ mRNA expression compared to normal peripheral blood or bone marrow mononuclear cells. This study investigated the cytotoxic effects of rosiglitazone maleate, a pure PPARɣ agonist, in vitro in HL-60 cell line. This study obtained results which can provide guidance for future studies. Whether the PPARy agonist rosiglitazone maleate may provide additive effects in refractory or relapsing cases of acute leukemia may be set as an objective for the future studies.
Keywords
Rosiglitazone maleate , PPAR , Acute leukemia , HL 60 cell line
Journal title
Saudi Pharmaceutical Journal(SPJ)
Journal title
Saudi Pharmaceutical Journal(SPJ)
Record number
2684697
Link To Document